The stock market rebounded on Monday as investors looked past of a possible government shutdown. This might delay the release of monthly jobs report later in the week.
Overall, S&P 500 rose 0.3% to 6,661, while NASDAQ went up 0.5% to 22,591.
Tweet of the Day
Good stuff https://t.co/3osPWhiS1z
— David Sharek (@GrowthStockGuy) September 27, 2025
Chart of the Day
Here is the one-year chart of TG Therapeutics (TGTX) as of September 4, 2025, when the stock was at $32.
TG Therapeutics saw strong growth driven by its flagship MS therapy, Briumvi. Last quarter, the company delivered 325% profit growth on 92% higher revenue, with Briumvi sales up 92% year-over-year.
Briumvi was prescribed to nearly one in three new IV anti-CD20 patients in the US, showing broad uptake across academic centers, community neurology practices, and the VA system. The company also reported its highest number of new patient enrollments since launch, two-and-a-half years ago.
TG Therapeutics expanded its MS portfolio by developing a self-injected version of Briumvi, simplifying IV dosing to a single infusion, and testing new treatments, including a CAR-T therapy for progressive MS and Briumvi for myasthenia gravis.
Outside the US, Briumvi rolled out through its partner Neuraxpharm, with approvals in the EU, UK, Switzerland, and Australia.
TGTX was sold from our Growth Portfolio, as it is not moving higher.
